The effect of combinated treatment of a metastatic HER2-positive stomach cancer

The effect of combinated treatment of a metastatic HER2-positive stomach cancer

Trastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alone. Authors demonstrate the case of the successful...

Full description

Bibliographic Details
Main Authors:	R A Khvastunov, A Yu Nenarokomov, S E Tolstopiatov, K G Babina
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2014-12-01
Series:	Современная онкология
Subjects:	her2-povitive gastric cancer trastuzumab target therapy
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26960

Similar Items

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
by: Kahraman S, et al.
Published: (2021-07-01)

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01)

Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report
by: A. A. Kachmazov, et al.
Published: (2019-12-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
by: Benjamin Daniels, et al.
Published: (2019-09-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)

Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
by: Elda eTagliabue, et al.
Published: (2014-11-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
by: Fu XM, et al.
Published: (2018-09-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
by: A P Seryakov, et al.
Published: (2014-06-01)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
by: Hyehyun Jeong, et al.
Published: (2021-01-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
by: Linehan AS, et al.
Published: (2021-02-01)

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
by: Zhou P, et al.
Published: (2016-04-01)

Trastuzumab: More Than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗
by: Erica L. Mayer, MD, MPH
Published: (2020-06-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
by: Han Y, et al.
Published: (2019-05-01)

Personalized approach to HER2-positive advanced breast cancertherapy
by: M B Stenina
Published: (2014-09-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

PTEN loss is associated with a poor response to trastuzumab in HER2- overexpressing gastroesophageal adenocarcinoma
by: Deguchi, Yasunori
Published: (2017)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
by: Lei L, et al.
Published: (2019-04-01)

HER2‐positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab‐based chemotherapy: A case report
by: Raffaele Longo, et al.
Published: (2020-12-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)